234 related articles for article (PubMed ID: 28416366)
41. A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis.
Fujita K; Yagi M; Moriwaki S; Yoshida M; Graham D
J Dermatol; 2021 Nov; 48(11):1640-1651. PubMed ID: 34435694
[TBL] [Abstract][Full Text] [Related]
42. Treatment of psoriasis with crisaborole.
Lee EB; Lebwohl MG; Wu JJ
J Dermatolog Treat; 2019 Mar; 30(2):156-157. PubMed ID: 29812961
[TBL] [Abstract][Full Text] [Related]
43. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
Eichenfield LF; Yosipovitch G; Stein Gold LF; Kalabis M; Zang C; Vlahos B; Sanders P; Myers DE; Bushmakin AG; Cappelleri JC; Olivadoti M; Paller AS
Pediatr Dermatol; 2020 Nov; 37(6):1030-1037. PubMed ID: 32981097
[TBL] [Abstract][Full Text] [Related]
44. Evaluating crisaborole as a treatment option for atopic dermatitis.
Ramachandran V; Cline A; Feldman SR; Strowd LC
Expert Opin Pharmacother; 2019 Jun; 20(9):1057-1063. PubMed ID: 31002539
[TBL] [Abstract][Full Text] [Related]
45. Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
Kubota-Ishida N; Matsuhira T; Kaji C; Kikuchi C; Tabata Y
Eur J Pharmacol; 2021 Sep; 906():174258. PubMed ID: 34139195
[TBL] [Abstract][Full Text] [Related]
46. Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
Ständer S; Yosipovitch G; Bushmakin AG; Cappelleri JC; Luger T; Tom WL; Ports WC; Zielinski MA; Tallman AM; Tan H; Gerber RA
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1742-1746. PubMed ID: 31132182
[TBL] [Abstract][Full Text] [Related]
47. Off-Label Therapeutic Potential of Crisaborole.
Makins C; Sanghera R; Grewal PS
J Cutan Med Surg; 2020; 24(3):292-296. PubMed ID: 32133868
[TBL] [Abstract][Full Text] [Related]
48. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial.
Hashim PW; Chima M; Kim HJ; Bares J; Yao CJ; Singer G; Chen T; Genece J; Baum D; Kimmel GW; Nia JK; Gagliotti M; Lebwohl MG
J Am Acad Dermatol; 2020 Feb; 82(2):360-365. PubMed ID: 31279028
[TBL] [Abstract][Full Text] [Related]
49. Utility of boron in dermatology.
Jackson DG; Cardwell LA; Oussedik E; Feldman SR
J Dermatolog Treat; 2020 Feb; 31(1):2-12. PubMed ID: 28789577
[No Abstract] [Full Text] [Related]
50. Crisaborole (Eucrisa) for atopic dermatitis.
Med Lett Drugs Ther; 2017 Feb; 59(1515):34-35. PubMed ID: 28222061
[No Abstract] [Full Text] [Related]
51. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Moustafa F; Feldman SR
Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
[TBL] [Abstract][Full Text] [Related]
52. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis.
Nazarian R; Weinberg JM
Curr Opin Investig Drugs; 2009 Nov; 10(11):1236-42. PubMed ID: 19876791
[TBL] [Abstract][Full Text] [Related]
53. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.
Ahluwalia J; Udkoff J; Waldman A; Borok J; Eichenfield LF
Drugs; 2017 Sep; 77(13):1389-1397. PubMed ID: 28681318
[TBL] [Abstract][Full Text] [Related]
54. Exacerbation of Pediatric Periorificial Dermatitis: A Novel Adverse Reaction.
Parker J; Neill B; Whitsitt J; Rajpara A; Aires D
J Drugs Dermatol; 2020 Apr; 19(4):428. PubMed ID: 32401455
[No Abstract] [Full Text] [Related]
55. Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment.
Eichenfield LF; Stein Gold LF
Semin Cutan Med Surg; 2017 Mar; 36(2 Suppl 2):S45-S48. PubMed ID: 28654711
[TBL] [Abstract][Full Text] [Related]
56. Biomarkers of response to topical crisaborole in patients with mild/moderate pediatric atopic dermatitis from minimally invasive tape strip transcriptome.
Fishbein AB; Mukherji J; Demczuk M; Buranosky B; Osborn J; Moreno C; LaRoche D; Paller AS; Lu KQ
J Am Acad Dermatol; 2024 Mar; 90(3):629-632. PubMed ID: 37924950
[No Abstract] [Full Text] [Related]
57. Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection.
Youn C; Dikeman DA; Chang E; Liu H; Nolan SJ; Alphonse MP; Joyce DP; Liu Q; Meixiong J; Dong X; Miller LS; Archer NK
Exp Dermatol; 2023 Apr; 32(4):425-435. PubMed ID: 36461082
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.
Ohba F; Matsuki S; Imayama S; Matsuguma K; Hojo S; Nomoto M; Akama H
J Dermatolog Treat; 2016 Oct; 27(5):467-72. PubMed ID: 27080209
[TBL] [Abstract][Full Text] [Related]
59. Contact allergy to crisaborole in a paediatric patient with atopic dermatitis.
Arora P; Neeley A
Contact Dermatitis; 2023 Oct; 89(4):309-310. PubMed ID: 37525478
[No Abstract] [Full Text] [Related]
60. Crisaborole 2% Ointment (Eucrisa
Gupta AK; Versteeg SG; Abramovits W; Vincent KD
Skinmed; 2017; 15(5):377-380. PubMed ID: 29139367
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]